Тилатамиг самротекан

Rec. INN (наименование, зарегистрированное ВОЗ)

2868265-77-2

immunoglobulin G1-kappa/G1-lambda, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)] and anti-[Homo sapiens EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], Homo sapiens monoclonal antibody, bispecific, conjugated on 6 cysteinyl residues to samrotecan;
H-gamma1 heavy chain anti-MET Homo sapiens (1-446) [VH (Homo sapiens IGHV1-8*01 (95.9%) -(IGHD) -IGHJ3*01 (100%), CDR-IMGT [8.8.9] (26-33.51-58.97-105)) (1-116)-Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v33 CH3 S22, A24, V86 (hole), G1v75 CH3 C5 (CH1 R120 (213) (117-214), hinge 1-15 (215-229), CH2 L1.3>F (233), L1.2>E (234), P116>S (330) (230-339), CH3 Y5>C (348), E12 (355), M14 (357) T22>S (365), L24>A (367), Y86>V (406) (hole) (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with L-kappa light chain anti-MET Homo sapiens (1'-214') [V-KAPPA (Homo sapiens IGKV1-5*03 (92.6%) -IGKJ4*01 (90.9%) V124>L (104'), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153'), V101 (191') (108'-214')];
H-gamma1 heavy chain anti-EGFR Homo sapiens (1''-454'') [VH (Homo sapiens IGHV1-69*06 (83.7%) -(IGHD) -IGHJ1*01 (100%), CDR-IMGT [8.8.17] (26''-33''.51''-58''.97''-113'')) (1''-124'') -Homo sapiens IGHG1*03, G1m3, nG1m1 CH1 R120, CH3 E12, M14, G1v39 CH2 F1.3, E1.2, S116, G1v32 CH3 W22 (knob), G1v74 CH3 C10, G1v58 CH1 C5, h V5 (CH1 F5>C (133''), R120 (221'') (125''-222''), hinge 1-15 C5>V (227'') (223''-237''), CH2 L1.3>F (241''), L1.2>E (242''), P116>S (338'') (238''-347''), CH3 S10>C (361''), E12 (363''), M14 (365''), T22>W (373'') (348''-452''), CHS (453''-454'')) (125''-454'')], (133''-126''')-disulfide with L-lambda2 light chain anti-EGFR Homo sapiens (1'''-217''') [V-LAMBDA (Homo sapiens IGLV2-14*05 (94.9%) -IGLJ2*01 (90.9%), CDR-IMGT [9.3.11] (26'''-34'''.52'''-54'''.91'''-101''')) (1'''-111''') -Homo sapiens IGLC2*01 (98.1%), LC2v58 C10, V126, S10>C (126'''), C126>V (216''') (112'''-217''')]; dimer (225-233'':228-236'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of l-cysteinyl residues 233, 236, 219'', 225'', 228'' and 214''' with radical group 1-[(2S,5S)-1-{[(9S)-9-ethyl-9-hydroxy-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-4-yl]amino}-2-methyl-1,4,7,35-tetraoxo-5-(propan-2-yl)-10,13,16,19,22,25,28,31-octaoxa-3,6,34-triazaheptatriacontan-37-yl]-2,5-dioxopyrrolidin-3-yl (samrotecan)

Поделиться этой страницей